found that IL-33 increased the number of ILC2s in adipose tissue, reduced the body weight and fat mass, and improve glucose homoeostasis of high-fat-fed mice, suggesting that the IL-33/ILC2 pathway may be a novel way to treat obesity and metabolic disorders. Here, IL33 is linked to metabolic disease.